Protagonist Therapeutics Inc
Protagonist Therapeutics Inc is listed today as Protagonist Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2015 | $18 M | No. 2 | $10 to $50 million | equity | SEC | |
| May 2013 | $7 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Protagonist Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $46.02 million (100%).
Annual report (SEC XBRL) · Dec 2025
Protagonist Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Jul 2015).
SEC Form D · Jul 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2015
Products and services#
No products or services of Protagonist Therapeutics Inc are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Canaan Partners X LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| Canaan X L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| Johnson & Johnson Development Corp Et Al | Company | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Lilly Ventures Fund I LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| LV Management Group, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.
Largest shareholders today
Institutions holding Protagonist Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$1.5 B16.45%
- Farallon Capital Management, L.L.C.$907 M9.86%
- RTW Investments, LP$713 M7.75%
- UBS Group AG$557 M6.06%
- Vanguard Portfolio Management LLC$517 M5.62%
- Wellington Management Group LLP$499 M5.43%
- State Street Corp$490 M5.33%
- Vanguard Capital Management LLC$408 M4.44%
- Invesco Ltd.$400 M4.35%
- Johnson & Johnson$345 M3.75%
- Geode Capital Management, LLC$254 M2.76%
- Price T Rowe Associates Inc /MD/$253 M2.76%
- Janus Henderson Group Ltd.$221 M2.41%
- Woodline Partners LP$199 M2.16%
- Bank Of America Corp /de/$193 M2.10%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dinesh V. Patel, PhD | Executive officer | Jul 2015 |
| Dinesh Patel, PhD | Executive officer | Jun 2013 |
| Armen V. Shanafelt, Ph.D. | Director | Jul 2015 |
| Asish K. Xavier, Ph.D. | Director | Jul 2015 |
| Dinesh V. Patel, PhD | Director | Jul 2015 |
| Harold E. Selick, Ph.D. | Director | Jul 2015 |
| Michael K. Panaccio, Ph.D. | Director | Jul 2015 |
| Paul F. Truex | Director | Jul 2015 |
| Armen Shanafelt | Director | Jun 2013 |
| Asish K. Xavier | Director | Jun 2013 |
| Dinesh Patel, PhD | Director | Jun 2013 |
| Harold Selick | Director | Jun 2013 |
| Nicholas Peace | Director | Jun 2013 |
Went public since 2016. Its SEC number is that of a company listed on a stock exchange.